Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AAA inks deal for prostate cancer diagnostic
March 2018
SHARING OPTIONS:

SAINT-GENIS-POUILLY, France—An exclusive worldwide license agreement was struck last month between Advanced Accelerator Applications S.A. (AAA), a Novartis company, and Cancer Targeted Technology. The companies will develop and market the investigational new drug product F-18-labeled CTT1057, a ligand of prostate-specific membrane antigen (PSMA) for positron emission tomography imaging of prostate cancer. Though specific financial details were not disclosed, this deal includes an upfront licensing fee, milestone payments and royalties.
 
Dr. Susanne Schaffert, chairperson and president of AAA, remarked, “This agreement expands our position in the important prostate cancer space. PSMA diagnostics represent an accurate staging and risk assessment tool with the potential to change patient management decisions. CTT1057 is highly complementary to our existing F-18 PET portfolio and AAA is well suited to exploit this opportunity with our proven manufacturing and development capabilities.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.